Airija - anglų - HPRA (Health Products Regulatory Authority)

dexcel pharma gmbh - atorvastatin calcium trihydrate - film-coated tablet - 20 milligram(s) - hmg coa reductase inhibitors; atorvastatin

Airija - anglų - HPRA (Health Products Regulatory Authority)

dexcel pharma gmbh - atorvastatin calcium trihydrate - film-coated tablet - 40 milligram(s) - hmg coa reductase inhibitors; atorvastatin

Malta - anglų - Medicines Authority

dexcel pharma gmbh carl-zeiss-straße 2 63755 alzenau, germany - ciclosporin - soft capsule - ciclosporin 25 mg - immunosuppressants

Malta - anglų - Medicines Authority

dexcel pharma gmbh carl-zeiss-straße 2 63755 alzenau, germany - ciclosporin - soft capsule - ciclosporin 50 mg - immunosuppressants

Malta - anglų - Medicines Authority

dexcel pharma gmbh carl-zeiss-straße 2 63755 alzenau, germany - ciclosporin - soft capsule - ciclosporin 100 mg - immunosuppressants

Izraelis - anglų - Ministry of Health

dexcel pharma technologies ltd - clopidogrel as besylate - film coated tablets - clopidogrel as besylate 75 mg - clopidogrel - clopidogrel - secondary prevention of atherotrombotic eventsclopidogrel is indicated in:• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome - non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.prevention of atherothrobmotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.

Airija - anglų - HPRA (Health Products Regulatory Authority)

dexcel pharma gmbh - isosorbid-5-mononitrat - prolonged-release tablet - 60 milligram(s) - organic nitrates; isosorbide mononitrate

Malta - anglų - Medicines Authority

dexcel pharma gmbh carl-zeiss-straße 2 63755 alzenau, germany - tablet - amlodipine 10 mg - calcium channel blockers

Izraelis - anglų - Ministry of Health

dexcel pharma technologies ltd - valsartan - film coated tablets - valsartan 40 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

Izraelis - anglų - Ministry of Health

dexcel pharma technologies ltd - valsartan - film coated tablets - valsartan 80 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.for treatment of hypertension.